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1. Introduction 
1.1 The Sonic hedgehog pathway 
 
The Sonic hedgehog (Shh) signalling pathway plays a fundamental role in a multitude of 
biological processes occurring in embryonic and adult tissues across the metazoa, such 
as cell proliferation, tissue patterning and cell fate specification (Ingham et al. 2006, 
Ingham et al. 2011). Its key ligand, the Shh protein, is codified by the Sonic hedgehog 
gene, which belongs to the vertebrate hedgehog gene family together with Desert and 
Indian hedgehog (Avaron et al. 2006). These three genes are homologous to the Dro-
sophila hedgehog gene (HH), on which early studies of hedgehog signalling were mainly 
conducted (Ingham et al. 2011, Robbins et al. 2012). Shh is essential, among others, for 
patterning and morphogenesis of the embryonic central nervous system (Machold et al. 
2002). During neural tube development, the Shh protein is secreted in the notochord and 
floor plate, hereby playing a central role in the dorso-ventral polarization process of the 
developing central nervous system (Jessell 2000). The indispensability of hedgehog sig-
nalling for the overall brain development has been underlined by studies on morphoge-
netic pathologies commonly associated with disruption of the Sonic hedgehog pathway, 
such as holoprosencephaly (Nanni et al. 1999). Holoprosencephaly defines the inability 
of the prosencephalon to divide itself into the cerebral hemispheres, and mutations of 
PTCH1 and SHH, which represent key regulators of the hedgehog pathway, have been 
demonstrated to cause this type of dysmorphology (Nanni et al. 1999). The molecular 
characterization of the Sonic hedgehog pathway has encountered considerable difficul-
ties, many of which are probably to ascribe to the hydrophobic nature of the Sonic 
hedgehog protein (Mann et al. 2004). Shh is translated as a 45 kDa precursor protein, 
which is than cleaved auto-catalytically into two peptides before secretion (Bumcrot et al. 
1995), whereas the Shh-N (amino-terminal) peptide acts as the proper Shh-signalling 
activator (Hammerschmidt et al. 1997). The Shh protein binds to the heterodimeric 
Patched-Smoothened receptor complex, therefore initiating Shh signalling activation 
(Figure 1). If Shh is absent, Patched (Ptch) represses the activity of Smoothened (Smo), 
a transmembrane protein, which belongs to the Frizzled family of receptors, thus inacti-
vating the Sonic hedgehog pathway (Taipale et al. 2002). Upon binding of Shh to 
Patched, the Sonic hedgehog pathway is activated through Smoothened disinhibition 
(Ingham et al. 1991). In vertebrates, the glioma-associated oncogene family zinc finger 
proteins (Gli) are the ultimate effectors in the transduction of Sonic hedgehog signalling 
(Ingham et al. 2001), whereas the molecular mechanisms involved in the modulation of 
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the Gli transcription factors remain poorly understood (Ingham et al. 2011). Gli1 displays 
exclusively activating properties on the transcription of Shh target genes (Bai et al. 
2004). Gli2 and Gli3, on the other hand, present a double molecular function. Their full-
length forms act as transcriptional activators under the control of Smoothened, but also 
give rise, in absence of Shh, to repressive Gli forms after removal of specific C-terminal 
domains (Sasaki et al. 1999, Robbins et al. 2012).  
 
 
 
 
 
 
In the cerebellum, Shh is fundamental for the proliferation of cerebellar granule neuron 
precursor cells (CGNPs) in the external granule layer (Wechsler-Reya et al. 1999)  and 
persistent Shh activation is able to drive the formation of a particular, Shh-dependent 
medulloblastoma subgroup (Pietsch et al. 1997, Northcott et al. 2012). Furthermore, 
dysregulation of the Shh pathway plays a role in the induction of tumors occurring in dif-
ferent human tissues, such as Basal cell carcinoma (Athar et al. 2014) or Pancreatic 
 
Figure 1. The Sonic hedgehog pathway. In absence of Sonic hedgehog (Shh), Patched inhibits 
Smoothened therefore inactivating Sonic hedgehog signalling. The binding of Shh to the Patched receptor 
leads to a conformational change and disinhibition of Smoothened. On its behalf, Smoothened induces 
the activation of the Gli transcription factors (Gli
a
), whereas the molecular interaction between Smo and 
Gli remains poorly understood, especially in vertebrates (Robbins et al. 2012 for review). Gli1 acts exclu-
sively as a transcriptional activator. Gli2 and Gli3, on contrary, present an activating full-length (Gli
fl
) as 
well as a repressive form (Gli
r
), the latter of which is generated through post-translational modification of 
the Gli1 and Gli2 proteins in absence of Shh. 
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ductal carcinoma (Lauth et al. 2011). Molecules targeting different components of the 
Sonic hedgehog pathway, such as the Smoothened  inhibitor Vismodegib, have already 
been subject of clinical trials aiming at the consolidation of novel therapeutic approaches 
against Shh-driven neoplastic pathologies (Sekulic et al. 2012). 
1.2 The Wnt pathway 
 
The Wnt (Wingless related integration site) pathway is a highly conserved signalling 
pathway, which was first discovered due to its role in carcinogenesis (Nusse et al. 1982) 
and body axis formation during embryonic development (Klaus et al. 2008). Up until now, 
three different Wnt-associated pathways have been identified: the canonical Wnt path-
way (also called Wnt/ β-Catenin pathway), the non-canonical planar cell polarity (PCP) 
pathway and the non-canonical Wnt/ calcium pathway (Komiya et al. 2008). As far as 
molecular mechanisms and biological implications are concerned, the Wnt/ β-Catenin 
pathway remains better understood than the non-canonical Wnt pathways (Freese et al. 
2010). Mutational analysis of Wnt-related genes was able to elucidate the importance of 
Wnt for a wide range of developmental processes (Logan et al. 2004 for review), includ-
ing, among others, gastrulation (Barrow et al. 2003) or anterior-posterior body axis ex-
tension (Yamaguchi et al. 1999). In the central nervous system, canonical Wnt signalling 
is fundamental for forebrain development (Kim et al. 2000, Freese et al. 2010) in a dose- 
and gradient-dependent manner (Popperl et al. 1997). With particular regard to embry-
onic and postnatal cortical development, Wnt/ β-Catenin signalling has been shown to 
regulate the proliferation of neuronal cortical progenitor cells of the ventricular zone as 
well as neuronal lineage choice (Chenn et al. 2002, Backman et al. 2005, Pöschl et al. 
2013). In cerebellar development, the importance of Wnt/ β-Catenin has been underlined 
by studies showing that constitutional Wnt/ β-Catenin activation leads to an overall dis-
ruption of the cerebellar histological architecture and impaired proliferation of granule 
neuron precursor cells (Lorenz et al. 2011, Pöschl et al. 2013). In particular, a time-
dependent Wnt/ β-Catenin activation or downregulation as well as the interplay with the 
Sonic hedgehog pathway appear to be fundamental for normal cerebellar development 
(Selvadurai et al. 2011, Pöschl et al. 2013). In canonical Wnt signalling (Clevers et al 
2012 for review), Wnt proteins bind to an heterodimeric receptor complex (Figure 2) 
consisting of the 7-transmembrane Frizzled receptor (Fz) (Janda et al. 2012) and the 
LRP5/6 protein (Pinson et al. 2000). The following transduction of the Wnt signal through 
β-Catenin stabilization is regulated by the cytoplasmic destruction complex, which com-
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prises Axin, Adenomatous polyposis coli (APC), Dishevelled (Dvl), CK1 and GSK3 
(Aberle et al. 1997, Clevers et al. 2012). In the absence of Wnt, Axin binds β-Catenin 
and the serine/ threonine kinases CK1 (α/δ) and GSK3 (α/β) subsequently phosphory-
late β-Catenin leading to its ubiquitination and proteasomal degradation (Aberle et al. 
1997, Clevers et al. 2012). Wnt proteins, on the other hand, induce a conformational 
change of the Frizzled/LRP receptor complex followed by phosphorylation of LRP6, 
which is necessary for Axin-LRP6 binding and therefore for the disruption of the cyto-
plasmic destruction complex (Tamai et al. 2004). As a consequence, β-Catenin is stabi-
lized and shifted to the nucleus, where it interacts with transcription factors of the 
TCF/LEF family, ultimately leading to Wnt target genes expression (Behrens et al. 1996). 
 
 
 
 
The Wnt/ β-Catenin pathway has been demonstrated to play an essential role in the reg-
ulation of stem cell renewal, cell differentiation (Korinek et al. 1997, Ten Berge et al. 
2011) and ultimately- oncogenesis (Klaus et al. 2008). APC mutations, for instance, are 
 
Figure 2. The Wnt/ β-Catenin pathway. In the absence of Wnt, β-Catenin is phosphorylated by Glycogen 
Synthase Kinase 3 (GSK3) and the CK1-kinase group, which are part of the cytoplasmic destruction com-
plex, together with Dishevelled (Dvl), Axin and Adenomatous Polyposis Coli (APC). After phosphorylation 
and subsequent ubiquitination, β-Catenin is inactivated through proteasomal degradation. If present, Wnt 
binds the heterodimeric Frizzled-LRP5/6 receptor, which undergoes a conformational transformation. As a 
result, Axin binds to phosphorylated LRP5/6, thus disrupting the cytoplasmic destruction complex. Conse-
quently, β-Catenin is stabilized and shifted to the nucleus (Clevers et al. 2006 for review). 
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associated with Familiary Adenomatous Polyposis (FAP) as well as sporadic colorectal 
cancer (Kinzler et al. 1991, Kinzler et al. 1996). With regard to CNS malignancies, a par-
ticular subgroup of medulloblastoma arising from the dorsal brainstem might be driven 
by Wnt activation (Gibson et al. 2010) and simultaneous Shh and Wnt activation may 
characterize Embryonal tumors with multi-layered rosettes (ETMRs), a subset of CNS-
PNETs (Korshunov et al. 2012, Picard et al. 2012). 
1.3 Embryonal brain tumors 
 
Embryonal brain tumors are the largest group of malignant CNS tumors in children, often 
presenting as poorly differentiated, highly malignant neoplasms with small, round cells 
and high cellularity (Grech-Sollars et al. 2012, Sin-Chan et al. 2014, Wesseling 2014). 
Medulloblastoma, Primitive neuroectodermal tumors of the CNS (CNS-PNETs) and Atyp-
ical teratoid/ rhabdoid tumors (AT/RTs) are typical members of this tumor group (Figure 
3). 
   
 
 
 
 
 
Figure 3. Embryonal brain tumors. Taylor et al. were the first to delineate a molecular classification of 
medulloblastoma into four groups; namely Wnt, Sonic hedgehog, Group 3 and Group 4. As far as CNS-
PNETs are concerned, the 2007 WHO Classification of Tumours of the Central Nervous System defines 
the following histological subcategories: Neuroblastoma, Ganglioneuroblastoma, Medulloepithelioma and 
Ependymoblastoma. More recently, a new PNET subset called „ETANTR“ (embryonal tumor with abun-
dant neurop il and true rosettes) was delineated (Gessi et al. 2009). Following increasing evidence that 
Ependymoblastomas, Medulloepitheliomas and ETANTRs probably represent a single tumor entity, in 
2010 Paulus and Kleihues coined the term ETMR (Embryonal tumor with multilayered rosettes), which 
regroups these types of tumors. 
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Medulloblastoma 
Medulloblastoma is the most common malignant brain tumor of the childhood (Remke et 
al. 2013). The incidence of medulloblastoma in the USA resides around 9.6 per million 
for pediatric cases and 0.54 per million for adult cases (Thorne et al. 1994, Giordana et 
al. 1999), with other countries displaying similar incidence (Gjerris et al. 1998). The clini-
cal manifestation of medulloblastoma often comprises symptoms typically associated 
with increased intracranial pressure, such as nausea/vomiting or headaches, as well as 
cerebellar signs like ataxia or oculomotoric disorders (Alston et al. 2003). Metastatic dis-
semination through cerebral fluid in the craniospinal axis is a major prognostic factor and 
challenging clinical aspect in the treatment of medulloblastoma (Gajjar et al. 2006, Wu et 
al. 2012). The 5-year survival rate ranges between 65% for high-risk disease and 89% 
for average risk disease (Remke et al. 2013), with the adult cases presenting a worse 
prognosis (Smoll 2012). The 2007 WHO classification of brain tumors, based on which 
medulloblastoma is diagnosed in clinical practice, includes five histological subtypes: 
classic, desmoplastic/nodular, large-cell, anaplastic and medulloblastoma with extensive 
nodularity (Louis et al. 2007). All histological subtypes are classified as WHO grade IV 
tumors, representing the highest grade of malignancy (Louis et al. 2007). A further sub-
division of medulloblastoma in four molecular groups, namely Shh-induced, Wnt-
induced, Group 3 and Group 4 tumors (Figure 3), has recently been delineated 
(Northcott et al. 2012). Besides array-based expression patterns, the cellular origin of 
medulloblastoma subgroups has been subject of recent investigations. Shh-associated 
medulloblastoma appears to arise from cerebellar granule neuron precursors (GNPs) 
(Schüller et al. 2008) or cochlear granule neuron precursors (Grammel et al. 2012), 
whereas Wnt-induced medulloblastoma might take origin from dorsal brainstem precur-
sor cells (Gibson et al. 2010). The current therapeutic approach for medulloblastoma is 
multimodal, consisting of a combination of surgical resection, radiation of the tumor site 
and the craniospinal axis, and chemotherapy (Roussel et al. 2011). Neurological dys-
functions and cognitive impairment are the main side effects of this course of therapy 
(Ris et al. 2001), giving rise to the need for specific, targeted therapies. Based on the 
newly discovered molecular clustering of medulloblastoma, some subgroup specific 
therapies, especially for the Shh-dependent group, have already been matter of experi-
mental studies (Taipale et al. 2000) and clinical trials (Rudin et al. 2009).  
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Embyonal tumors with multi-layered rosettes 
CNS-PNETs, previously known as supratentorial PNETs, make up about 3-5% of all pe-
diatric brain tumors (Picard et al. 2012). These tumors mainly originate in the cerebral 
hemispheres and typically feature a variable histological presentation, including either 
poor differentiation or neuronal, ependymal and glial elements (Louis et al. 2007). Simi-
larly to medulloblastoma, CNS-PNETs often show the tendency to disseminate in the 
leptomeningeal space (Pizer et al. 2006). The current therapy protocols for CNS-PNETs, 
which resemble standard medulloblastoma treatment (Pizer et al. 2006), are associated 
with a poor prognosis not reaching 50% of survival after 3 years (Timmermann et al. 
2006). For this reason new and specific therapeutic approaches for CNS-PNETs are 
highly desirable. In comparison to medulloblastoma, for which an array-based molecular 
characterization has been carried out (Northcott et al. 2012), the molecular and cellular 
underpinnings of CNS-PNETs remain widely unknown (Li et al. 2005). According to the 
2007 WHO classification of brain tumors (Figure 3), CNS-PNETs are divided into four 
histological groups:  neuroblastomas, ganglioneuroblastomas, medulloepitheliomas and 
ependymoblastomas (Louis et al. 2007), whereas a particular subset of CNS-PNETs 
presents multi-layered rosettes on histological assessment (Korshunov et al. 2010). The 
diagnostic classification of this particular tumor entity was poorly defined in the past 
(Wesseling 2014), leading to divergent definitions, such as ependymoblastoma, or –
recently- ETANTR (Embryonal tumor with abundant neuropil and rosettes) (Korshunov 
et al. 2010). Li et al. were the first to discover the amplification of a chromosome 
19q13.41 miRNA polycistron (C19mC) as a common feature within a particular subgroup 
of PNETs with “ependymoblastic” histological features (Li et al. 2009), thus delineating a 
new diagnostic entity comprising the formerly applied terms of ependymoblastoma, me-
dulloepithelioma, and ETANTR, namely ETMRs (Embryonal tumors with multi-layered 
rosettes) (Korshunov et al. 2010, Eberhart 2011). 
1.4 Interaction of Shh and Wnt/ β-Catenin in embryonal brain tumors 
 
A possible interaction between the Shh and Wnt pathway in the central nervous system, 
particularly in terms of an antagonistic role of Wnt over Shh activation, has been matter 
of study in recent years (Yu et al. 2008, Tang et al. 2010). The hypothetical inhibitory 
effect of Wnt on Shh might be corroborated by findings showing that Wnt is able to an-
tagonize Shh during neural tube patterning (Alvarez-Medina et al. 2008). In the cerebel-
lum, constitutional activation of Wnt was demonstrated to be able to down-regulate the 
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Shh pathway and inhibit the Shh-driven proliferation of cerebellar granule neuron pre-
cursor cells as well as Shh-dependent medulloblastoma tumor growth in mice (Lorenz et 
al. 2011, Pöschl et al. 2014). Hence, the antagonizing effect of Wnt over Shh should be 
further investigated with respect to a possible use of Wnt-activating substances, such as 
Lithium (Lancaster et al. 2011), in the therapy of Shh-driven medulloblastoma. Interest-
ingly, recent array-based studies on CNS-PNETs identified a molecular tumor cluster, 
called “group 1” PNET, which displayed both Wnt and Shh upregulation (Picard et al. 
2012). Both “group 1” PNETs and the newly defined EMTRs appeared to be character-
ized by frequent C19mC amplification and overexpression of the molecular marker 
LIN28 (Korshunov et al. 2012, Picard et al. 2012), which suggests that EMTRs and 
“Group 1” PNETs might actually represent the same pathological entity. Hence, it is pos-
sible to propose the hypothesis that the observed inhibitory effect of Wnt over Shh in the 
cerebellum might be spatially-related and not applicable to other regions of the central 
nervous system, such as the forebrain. On the contrary, a possible synergistic and tu-
mor-inducing role of simultaneously activated Wnt and Shh in EMTR formation should 
be subject of further research. 
1.5 Aim of this study 
 
This work intends to investigate the diverging role of synchronistic Wnt and Shh activa-
tion in Shh-dependent medulloblastoma and Embryonal tumors with multi-layered ro-
settes, with particular regard to a possible therapeutic approach. A series of in vitro and 
in vivo experiments was carried out, aiming at the possible use of Lithium, a Wnt activa-
tor, in the therapy of Shh-driven medulloblastoma. Furthermore, the first conditional 
mouse model for Embryonal tumors with multi-layered rosettes (ETMR) was established 
and a possible role of Wnt and Shh upregulation in ETMR formation has been postulat-
ed. 
2. Material and methods 
2.1 Transgenic mice 
 
Math1-cre mice 
Math1-cre mice are transgenic mice, which carry a P1 bacteriophage Cre recombinase 
sequence under the control of a 1.4-kb upstream Math1 (also called: Atoh1) promotor. 
This results in a specific expression of Cre recombinase in Math1-expressing granule 
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neuron precursors (GNPs) of the cerebellum (Matei et al. 2005, Schüller et al. 2007). 
The following primers were used to detect the presence of the Math1-cre construct: 
Cre Fw 5´- TCCGGGCTGCCACGACCAA - 3´ 
Cre Rv 5´- GGCGCGGCAACACCATTTT - 3´ 
From Heine et al. 2009, annealing temperature: 65 ºC 
 
SmoM2Fl/FL mice 
SmoM2Fl/Fl mice bear a modified gene sequence of the Smoothened (Smo) transmem-
brane protein, which is a key regulator in Sonic Hedgehog signalling (see introduction, 
Figure 1). The W539L point mutation of the Smoothened gene, defined as SmoM2 muta-
tion, leads to autonomous Smoothened activation and therefore to constitutional Sonic 
hedgehog activation (Xie et al. 1998, Mao et al. 2006). A polyadenilation (4xpA) stop 
sequence upstream of SmoM2 is flanked by two loxP sites. In presence of Cre recom-
binase, the 4xpA stop sequence is excised. This results in uninhibited SmoM2 transcrip-
tion and therefore Shh activation (Figure 4). 
 
 
 
 
 
Figure 4. The SmoM2
Fl/Fl
 transgenic construct. The SmoM2 mutation of the Smoothened (Smo) gene is 
preceded by an upstream, loxP-flanked stop sequence (polyadenilation sequence, 4xpA). In presence of 
Cre recombinase, the stop sequence is excised, leading to SmoM2 transcription and therefore Sonic 
hedgehog activation. 
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The following Primers were used to detect the presence of the SmoM2Fl/Fl allele: 
SmoM2 Fw 5´- AAGTTCATCTGCACCACCG - 3´ 
SmoM2 Rv 5´- TCCTTGAAGAAGATGGTGCG - 3´ 
From Jeong et al. 2004, annealing temperature: 60 ºC 
 
In order to achieve constitutional Shh activation in Math1-positive cells, Math1-cre and 
SmoM2Fl/Fl mice were bred (Figure 5) and Math1-cre::SmoM2Fl/+ mice were generated 
(Schüller et al. 2008). 
 
 
 
Ctnnb1(ex3)Fl/Fl mice 
Ctnnb1(ex3)Fl/Fl mice (Harada et al. 1999, Pöschl et al. 2013) are characterized by the 
presence of a modified β-Catenin (Ctnnb1) gene sequence, which consists of two loxP 
sites flanking Exon 3 (ex3) (Figure 6). Exon 3 codifies particular domains of the β-
Catenin protein, which include Glycogen synthase kinase 3 beta (GSKβ) phosphoryla-
tion sites. Through Cre-mediated recombination Exon 3 is excised, resulting in a trun-
Figure 5. Breeding scheme for generating Math1-cre::SmoM2
Fl/+
 and hGFAP-
cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 mice 
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cated β-Catenin  without phosphorylation sites but still intact ability to act as a transcrip-
tion factor (Harada et al. 1999). This leads to a stabilized β-Catenin and consequently 
Wnt activation (Barth et al. 1997).  
 
 
 
 
The following Primers were used to detect the presence of the Ctnnb1(ex3)Fl/Fl allele: 
Ctnnb1(ex3)Fl/Fl Fw 5´- CGTGGACAATGGCTACTCAA - 3´ 
Ctnnb1(ex3)Fl/Fl Rv   5´- TGTCCAACTCCATCAGGTCA - 3´ 
Annealing temperature: 60 ºC 
 
hGFAP-cre mice 
hGFAP-cre mice express Cre recombinase under the control of an upstream enhancing 
sequence, which consists of the promotor of human glial fibrillary acidic protein 
(hGFAP). The hGFAP promotor targets a wide range of cell populations of the brain, 
including neural precursors and glial cells (Zhuo et al. 2001). After generating 
Figure 6. The Ctnnb1(ex3)
Fl/Fl
 transgene.  Exon 3 of the β-Catenin (Ctnnb1) gene is located between 
two loxP sequences. Exon 3 codifies domains of the β-Catenin protein, which serve as phosphorylation 
sites for Glycogen synthase kinase 3 beta (GSK3B). When Cre recombinase is expressed, Exon 3 is re-
moved leading to β-Catenin stabilization through missing phosphorylation and therefore Wnt/ β-Catenin 
activation. 
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Ctnnb1(ex3)FlFlSmoM2Fl/Fl mice, hGFAP-cre and Ctnnb1(ex3)FlFlSmoM2Fl/Fl mice were 
crossed (Figure 5). The newly developed hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice 
enabled the achievement of a synchronistic activation of both Shh and Wnt/β-Catenin in 
the hGFAP-positive cell population. The following Primers were used to detect the pres-
ence of the hGFAP-cre  allele: 
hGFAP Fw 5´- ACTCCTTCATAAAGCCCTCG - 3´ 
hGFAP  Rv   5´- ATCACTCGTTGCATCGACCG - 3´ 
From Zhuo et al. 2001, annealing temperature: 65 ºC 
 
Ptch1+/- mice 
Ptch1 is a key regulator of Sonic hedgehog signalling (see Figure 1). Ptch1+/- mice 
(Goodrich et al. 1997) are a Shh-dependent medulloblastoma mouse model carrying a 
knocked-out Ptch1 allele (Figure 7), which is achieved as a result of homologous re-
combination: part of Exon 1 and all of Exon 2 of the Ptch1 gene are replaced by a con-
struct containing lacZ, a commonly used reporter gene (Juers et al. 2012), and a neo-
mycin resistance gene (Goodrich et al. 1997). Upon random loss of the wild-type Ptch1 
allele, Ptch1+/- mice eventually develop medulloblastoma. This occurs in about 15-20% 
of the Ptch1+/- mice (Oliver et al. 2005). The following Primers were used to detect the 
presence of the mutated Ptch1 allele: 
Ptch1 Fw 5´- GCCCTGAATGACTGCAGGACG - 3´ 
Ptch1  Rv   5´- CACGGGTAGCCAACGCTATGTC - 3´ 
Annealing temperature: 65 ºC 
 
NMRI-Nu/Nu mice 
NMRI-Nu/Nu mice are nude mice characterized by hairless skin from birth as well as 
thymus dysgenesis with subsequent T-lymphocytes depletion (Pantelouris et al. 1970, 
Pignata et al. 1996, Schlake 2001). A homozygote mutation of the FoxN1 (Forkhead box 
N1) gene, which is located on chromosome 11 in mice, is responsible for this particular 
phenotype (Nehls et al. 1994, Schorpp et al. 1997). Nude mice are a well-established 
murine model for immunological, oncological and transplantation studies due to their 
lack of competent T-lymphocytes (Zhang et al. 2012).   
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2.2 DNA extraction 
 
DNA for genotype verification through PCR and electrophoresis was extracted from 
mouse tail biopsies. Each biopsy was first treated with 500 µl Laird´s lyses buffer (200 
mM NaCl, 100 mM Tris buffer (pH 8.5), 5 mM EDTA, 0.2% SDS) and 10 µl Proteinase K 
(10mg/ml) on a thermo-shaker at 56ºC for at least 2 hours. Samples were than centri-
fuged (14.000 U) at room temperature for 5 minutes. The supernatant containing the 
DNA was then extracted into a new tube and 500 µl Isopropanol were added. After mix-
ing, the precipitated DNA became visible. Centrifugation at room temperature with 
14.000 U for 5 minutes was repeated. Finally, the remaining Isopropanol was discarded 
and the DNA pellet was re-suspended in DEPC water and then stored at 4ºC. 
2.3 Cell lines 
 
HEK 293T, UW473 and GL261 
HEK 293T cells arise from human embryonic kidney cells, which were originally trans-
formed with Adenovirus 5 DNA (Graham et al. 1977). UW473 is a human medulloblas-
toma cell line obtained from a pediatric tumor sample (Bobola et al. 2005, Castro-
Gamero et al. 2013). GL261 cells derive from the GL261 mouse glioma model. This mu-
rine model was first developed through application of a chemical carcinogen into the 
brain of C57BL/6 mice and then perpetuated by means of syngeneic transplantation 
(Maes et al. 2011). All three cell lines proliferated as adherent monolayers and were cul-
Figure 7. The Ptch1
+/-
 knockout transgene.  Part of Exon 1 and all of Exon 2 of the Ptch1 gene are re-
placed through homologous recombination by a gene cassette containing a lacZ marker sequence and a 
neomycin resistance gene, thus resulting in Ptch1 knockout. 
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tured in DMEM medium with 10% fetal calf serum, 1% Glutamax (Invitrogen), 1% Peni-
cillin/Streptomycin (Invitrogen) and 1% HEPES buffer (Sigma).  
2.4 Primary cell culture 
 
Cerebellar granule neuron precursor cells 
Well plates were coated with 1x poly-L-ornithine (Sigma) from a 100x stock (10 mg/ml). 
Dilution was carried out in H2O and 0.2 µM sterile filters were used in order to preserve 
poly-L-ornithine. The plates were than incubated at 37ºC during mouse preparation al-
lowing poly-ornithine to polymerise. Mouse cerebella were dissected at postnatal day 5-7 
and put on ice in 15 ml Hanks buffered saline solution (Gibco, pH 7.4 Glucose 6 mg/L). 
After centrifugation at 4ºC for 5 minutes with 800 rpm, HBSS was discarded. 1 ml of 1x 
Trypsin/EDTA/DNAse (100 µg DNAse/ml, both Trypsin/EDTA and DNAse were from 
Sigma) was added and the cerebella were left 10 minutes in water bath for incubation. 
Trypsin was then inactivated with 2 ml of DMEM+10% fetal bovine serum (fetal bovine 
serum was inactivated at 56ºC for 30 minutes prior to usage). Next, the cerebella were 
centrifuged at 4ºC with 1500 G for 5 minutes. The fetal bovine serum medium was aspi-
rated and substituted with 5 ml HBSS solution. The pellets were dissolved by pipetting 
gently and a new centrifugation step (as above) was conducted. After discarding super-
natant HBSS, the pellets were re-suspended in 1 ml HBSS and spun as above. The 
HBSS remnant was extracted and the cells were put into suspension with serum-free 
culture medium with supplements (49 ml Neurobasal medium (1x), 1 ml b27 supplement 
(50x), 10 µl FGF-basic human (100 µg/ml), 10 µl EGF recombinant (mouse) (100 µg/ml), 
Glutamax 500 µl (200 mM), 500 µl Penicillin/Streptomycin (100x). All reagents were from 
Invitrogen). The poly-L-ornithine solution was removed and each well was washed with 
PBS once. Granule neuron precursors were then plated in serum-free culture medium 
with supplements at a concentration of 2 million cells/well and grown at 37°C and 5% 
CO2. 
Neural forebrain precursor cells 
Murine neural forebrain precursors were isolated from the ventricular zone at postnatal 
day 0 (P0). The mouse cerebrum was separated from the midbrain using a razor blade, 
in order to achieve a smooth frontal section through the occipital cerebral hemispheres. 
Basal forebrain structures, the bulbi olfactorii and choroid plexus tissue were removed. 
Tissue from both cerebral hemispheres was then suspended in 37ºC brain lysis buffer (5 
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ml Leibovitz´s medium (Pan-Biotech), 250 µl DNAse (Invitrogen), 50 µl Papain (Miltenyi 
Biotech), 5 µl of 500 mM EDTA). A cell suspension was then prepared by pipetting with 
a sterile 1000 µl filter tip for 5 minutes. The suspension was incubated at 37ºC in water 
bath for 20 minutes. The suspended cells were centrifuged at 1000 rpm at room temper-
ature for 5 minutes and re-suspended in 4ml of warm Leibovitz´s medium and centri-
fuged again for 5 minutes at room temperature. In presence of red blood cells, the wash-
ing with Leibovitz´s medium was repeated as described above. Neurosphere culture 
medium (45.5 ml DMEM-F12 (Pan-Biotech), 2 ml of 1M HEPES buffer (Sigma), 1 ml of 
b27 growth supplement (Invitrogen), 500 µl of Glutamax (200 mM, Gibco), 500 µl of 
Non-essential amino acids (100x, Sigma), 500 µl of Pen/Strep (100x, Invitrogen), 20 
ng/ml mouse epidermal growth factor (100 µg/ml, Invitrogen), 10 µl FGF-basic human 
(100 µg/ml)) was then used to bring cells in suspension. Before plating cells in 5 ml 
dishes the cell suspension was passed through a 70 µm cell strainer, in order to assure 
a single cell suspension. Cells were grown at 37°C and 5% CO2, cytokines (EGF, FGF) 
were supplemented every 3 days. 
2.5 Colorimetric MTT-assay 
 
The colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)- as-
say is a spectrophotometer-based method used to quantify cell growth or cytotoxicity 
rates (Finlay et al. 1986, Vistica et al. 1991). The tetrazolium salt MTT is chemically re-
duced by ribosomes in metabolic active cells, forming formazan crystals. The resulting 
change of solution colour is than quantified through spectrophotometrical absorbance 
measure. For this work, the Cell Proliferation Kit I (MTT) from Roche was used. Cells 
were first seeded in 100 µl in 96-well plates at a concentration of 2x104/well and incu-
bated (37ºC) in neurobasal culture medium with supplements (see also primary cell cul-
ture) for 16 hours. Spectrophotometrical absorbance was determined using the FLU-
Ostar Optima (BMG labtech) system. For lithium chloride treatment, start point of thera-
py was defined by adding 10 µl of the MTT reagent to at least three wells and adding the 
Solubilisation solution (100 µl) after 4 hours, in order to quantify cell viability at time point 
0 (T0). After 24 hours (T1), 10 µl of the MTT reagent were put into the remaining wells (at 
least in triplicates) for 4 hours, after which, the Solubilisation solution (100 µl) was added 
into each well. One well was left without MTT and served as a blank sample. The plates 
were let sit in the incubator overnight and the optical density (OD) at T0 and T1 was de-
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termined as follows: ODT – ODblank. Cell viability after 24 hours (T1) was calculated using 
the following formula: ODT0/ODT1= 100%/x.  
2.6 Lithium chloride treatment 
 
In our in vitro setting, lithium chloride was balanced with NaCl in order to achieve equal 
salt concentrations of 25 mM in every well. Lithium chloride dosage for in vivo treatment 
was chosen according to previous publications (Makoukji et al. 2012). Math1-
cre::SmoM2Fl/+ mice underwent daily intraperitoneal injections of either 50 mg/kg lithium 
chloride (LiCl) or sodium chloride (NaCl) for 10 days starting from P15. LiCl and NaCl 
were diluted in sterile H2O. 
2.7 Allotransplantation 
 
Forebrain tumor cells from hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice at postnatal day 0 
(P0) were isolated and put into primary culture for 4 days, as described above. After 
Xylazine-Ketamine anesthesia (Xylazine: 5mg/kg body weight, Ketamine: 100mg/kg 
body weight), the skin of NMRI-Nu/Nu mice was cut in order to expose the skull and a 
burr hole craniotomy was performed. A 2 µl suspension containing 400.000 forebrain 
tumor cells from hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice  were injected stereotacti-
cally into the brain. Counting the intersection between the coronal and sagittal suture 
(also called Bregma point) as position 0, following coordinates were used: caudal: 2.2 
mm, lateral (right): 2 mm, ventral: 2 mm. 
Transplanted mice were monitored for neurological dysfunctions on a daily basis and 
sacrificed upon occurrence of general or neurological symptoms. 
2.8 RNA extraction, cDNA synthesis and RT PCR 
 
Both cultured cells and tissue samples were first put into Eppendorf tubes and homoge-
nised with 750 µl TRlzol® (Invitrogen) reagent using a pipette, before proceeding with 
RNA extraction. The homogenised samples were let sit at room temperature for about 5 
minutes. 150 µl of chloroform were added to each tube. After mixing for 15 seconds, the 
samples were incubated at room temperature for 3 minutes. A centrifugation step with 
14.000 rpm at 4ºC was conducted for 15 minutes, after which the supernatant, RNA-
containing top layer was extracted into a new Eppendorf tube. The RNA was then pre-
cipitated with cold (4ºC) isopropanol and incubated at room temperature for 10 minutes. 
A centrifugation step was repeated as described above. Eventually, the RNA pellet be-
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came visible at the bottom of the tubes. The supernatant liquid was discarded and the 
RNA pellet was washed with 75% ethanol. After brief shaking, each sample was centri-
fuged for 5 minutes at 4ºC with 7500 rpm. Ethanol was discarded, and the RNA pellets 
were re-suspended in 24 µl DEPC water each. The RNA concentration was determined 
through Nanodrop 3300 technology (Thermo Fischer Scientific). cDNA Synthesis for RT 
PCR was performed using SuperScript® III First-Strand Synthesis Supermix (Invitrogen). 
Each component was mixed and centrifuged before use. For each RNA sample the re-
action mix consisted of the following reagents: 6 µl of RNA (in DEPC water, up to 5 µg 
RNA), 0.5 µl oligo(dT)20 primer (50 µM), 0.5 µl of random hexamers (50 ng/µl), 1 µl an-
nealing buffer , RNAse/DNAse-free water to bring the total volume up to 8 µl. After heat-
ing at 65ºC for 5 minutes in a thermo-cycler, the tubes were put on ice for 1 minute. 
Leaving the tubes on ice, the following solutions were added to each reaction mix: 10 µl 
First-Strand Reaction Mix (2x), 2 µl SuperScript® III/ RNaseOUTTM Enzyme Mix. The 
tubes were than mixed by vortexing and centrifuged briefly. The samples were incubated 
in a thermo-cycler for 5 minutes at 25ºC, 50 minutes at 50ºC and finally at 85ºC for 5 
minutes. Finally, the cDNA was cooled down on ice and stored at -20ºC.  
Reverse Transcriptase PCR (RT PCR)  
Reverse Transcriptase PCR (RT PCR) was carried out using the LightCycler® 480 
(Roche) technology and the LightCycler® 480 SYBR Green I Master Mix (Roche). SYBR 
Green is a fluorescent cDNA-intercalating dye, which is detected and quantified after 
each elongation step, therefore allowing cDNA quantification in real time. Each reaction 
mix contained the following agents: FastStart Taq DNA Polymerase and SYBR Green 
dye (Roche), 3 µl of cDNA, 1 µl forward primer and 1 µl reverse primer (primer stocks 
concentration: 100 pmol/µl). Before usage, each primer was diluted 1:10 in DNAse free 
water. A RT PCR program was conducted, which included the following steps: heat 
shock at 95ºC for 5 minutes (once), then 45-cycles containing the following steps: dena-
turation at 95ºC for 10 seconds, annealing at 57-62ºC for 10 seconds, elongation at 
72ºC for 15 seconds. 
Relative quantification was achieved by comparing cDNA levels between target genes 
and housekeeper genes (β2-Microglobulin (β2M)). Besides this, a calibrating sample 
was used for each LightCycler® run within a single experiment, in order to compensate 
variations of the reaction mix composition. All samples were analysed in triplicates. The 
following formula was applied for relative quantification: 
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NR=ET CpT(C) - CpT(S) x ER CpR(S) - CpR(C) 
NR= normalized ratio, E= primer efficiency, T= target gene, C= calibrating sample, R= 
housekeeper gene, S= sample, Cp= crossing point (number of cycles after which the 
SYBR Green detection threshold is reached). 
All primers were designed using the Primer3 software and ordered from Eurofins Ge-
nomics. Amplicon melting curves were analysed to determine the presence of a single 
PCR product, primer quality and primer efficiencies were calculated based on standard 
curves. Table 1 shows primer pairs sequences and efficiencies. 
Table 1. 
gene  sequence efficiency anneal-
ing 
β2M Fw CCTGGTCTTTCTGGTGCTTG 2.23 60ºC 
β2M Rv TATGTTCGGCTTCCCATTCT 
Axin2 Fw GCTGGTTGTCACCTACTTTTTCT 1.81 62ºC 
Axin2 Rv ATTCGTCACTCGCCTTCTTG 
Dkk1 Fw CTGACCACAGCCATTTTCCT 1.88 62ºC 
Dkk1 Rv ACGGAGCCTTCTTGTCCTTT 
Ptch1 Fw TATCCCTGCCCTGCGAGCGT 1.91 60ºC 
Ptch1 Rv CCTGCTGACACAGGGGCTTGT 
cMyc Fw  CTCAGTGGTCTTTCCCTACCCG 1.869 
(Reed et al. 2008) 
60ºC 
cMyc Rv TGTCCAACTTGGCCCTCTTGGC 
Tcf7l2 Fw AGCAGACAAACCCTCAAGGA 1.926 62ºC 
Tcf7l2 Rv TAAGTGCGGAGGTGGATTTC 
 
2.9 Histology and immunohistochemistry 
 
After dissection, all brains were fixed with 4% paraformaldehyde at 4ºC. For Hematoxylin 
and Eosin (H.E.) staining, the tissue was dehydrated, embedded in paraffin and sec-
tioned at 5 µm according to established protocols. For immunohistochemistry, 4 µm sec-
tions were gained from the paraffin-embedded tissue and rehydrated. Immunohisto-
chemical staining for Ki67 (primary antibody from Abcam, 1:200) was obtained using the 
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automated iView DAB Detection Kit (Ventana®). Histological imaging was performed us-
ing Olympus Bx41 and Bx50 microscopes with the Cell software or the Color view Soft 
imaging system (Olympus). 
2.10 Protein extraction and western blot 
 
Cell pellets or tissues were put into an Eppendorf tube and 50 µl cold (4ºC) Lysis buffer 
(50 mmol/L Tris-HCl (pH 8), 120 mmol/L NaCl, 0.5% Nonidet P-40, 1 mmol/L pheny-
metylsulfonyl fluoride (Sigma), 100 U/ml Aprotinin (Calciobiochem), 0.1 mol/L NaF) was 
added. The tubes were left on ice and stirred on an orbital shaker for 30 minutes. The 
samples were than centrifuged at 4ºC for 20 minutes with 12,000 G. The protein-
containing supernatant was than extracted and put into a new tube. Electrophoresis on 
10% sodium dodecylsulfate polyacrylamide gel was performed and blotting was con-
ducted on nitrocellulose membrane. Ponceau staining was used to estimate the loading 
of each well. 5% non-fat dry milk (BioRad) in PBS-Tween was utilized to block the mem-
branes for 2 hours at room temperature. Primary antibodies were diluted (Beta tubulin 
1:500 (Sigma), Gli2 1:500 (Abcam), Axin2 1:200 (Abcam)) in PBST and let incubate at 
4ºC overnight. An alkaline phosphatase-labelled goat secondary antibody and the CDP-
Star solution (Roche) were used for chemiluminescence detection.  
2.11 Statistical analysis 
 
The Prism5 software was used for statistical analysis. Survival data were obtained 
through Kaplan-Meyer curves and the Log-rank test served as significance test. P- val-
ues <0.05 were considered as significant. Survival curves for Math1-cre::SmoM2Fl/+ mice 
were drafted having n=15 LiCl and n=10 NaCl mice. Survival data for allotransplanted 
NMRI-Nu/Nu mice were calculated on n=8 animals. When comparing two groups with 
assumed Gaussian distribution and equal variances, the unpaired t-test was conducted. 
In case of not equal variances or an expected non-Gaussian distribution, the non-
parametric Mann-Whitney test was used. For RT PCR, western blot and MTT-assays a 
number of at least three samples was analysed for each experimental condition or 
mouse genotype.  
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3. Results 
3.1 Effects of activated Wnt/ β-Catenin signaling on Shh-dependent medullo-
blastoma formation 
3.1.1 In vitro treatment of granule neuron progenitors and medulloblastoma 
tumor cells with the Wnt agonist lithium chloride 
 
Lithium is a chemical element with psychotropic properties, which is commonly used to 
treat bipolar disorder as well as other psychiatric diseases (Geddes et al. 2004, 
Storosum et al. 2007), although the underpinnings of its biochemical effects remain only 
partially understood (Alda 2015). Among others, Lithium has been shown to act as an 
inhibitor of Glycogen synthase kinase 3 beta, a serine/threonine kinase also known as 
GSK3B (Klein et al. 1996, Stambolic et al. 1996, O'Brien et al. 2009). GSK3B is part of 
the so-called cytoplasmic destruction complex together with Axin, Adenomatosis polypo-
sis coli (APC), Dishevelled (Dvl), the CK1-Kinase group and GSK3A (Clevers 2006). 
This protein complex leads to phosphorylation, ubiquitination, and therefore proteasomal 
degradation of β-Catenin in the cytoplasm. (Aberle et al. 1997, Willert et al. 1999). 
Hence, Lithium is able to activate the Wnt/ β-Catenin pathway by inhibiting GSK3B and 
therefore preventing phosphorylation and subsequent degradation of β-Catenin 
(Stambolic et al. 1996). Previous results demonstrated an inhibitory effect of constitu-
tional Wnt/ β-Catenin activation  on Shh-dependent medulloblastoma formation in 
Math1-cre::SmoM2Fl/+::Ctnnb1(ex3)Fl/+ mice (Pöschl et al. 2014). In order to examine, 
whether a Wnt agonist might represent a suitable treatment option for patients with Shh-
dependent medulloblastoma, a series of in vitro and in vivo experiments was conducted, 
in order to inquire a possible inhibitory effect of lithium chloride (LiCl), a highly soluble 
lithium salt, which has been suggested to act as a Wnt/ β-Catenin activator in the cere-
bellum (Lancaster et al. 2011). First, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assays were carried out to investigate, whether the treat-
ment of medulloblastoma tumor cells with LiCl would result in a decrease of cell viability 
in vitro (Figure 8). Granule neuron precursor cells (GNPs), from which Shh-dependent 
medulloblastoma arise (Schüller et al. 2008), as well as medulloblastoma tumor cells 
from Math1-cre::SmoM2Fl/+ and Ptch1+/- mice, two well-known murine models for Shh-
induced medulloblastoma (Goodrich et al. 1997, Schüller et al. 2008), were isolated and 
put into primary culture for 16 hours. These cells were than treated with 10 mM LiCl for 
24 hours in parallel with HEK293T, UW473 and GL261 cell lines (see methods section), 
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which served as Shh-independent control cells. As a result, LiCl lead to a significant de-
crease of cell viability in Shh-dependent GNPs and tumor cells from Math1-
cre::SmoM2Fl/+ and Ptch1+/- mice when compared to control cells (p<0.01) (Pöschl et al. 
2014) (Figure 8). Thus, LiCl is able to inhibit proliferation of Shh-associated medullo-
blastoma cells in vitro (Pöschl et al. 2014). 
 
 
 
 
3.1.2 In vivo treatment of medulloblastoma using the Wnt agonist lithium chloride 
 
Following the in vitro investigations, in vivo experiments on Math1-cre::SmoM2Fl/+ mice 
were initiated, in order to examine, whether LiCl might unfold an inhibitory effect on tu-
mor formation in a murine medulloblastoma model. Math1-cre::SmoM2Fl/+ mice were 
treated with i.p. injections of 50 mg LiCl (n=15) or NaCl (n=10) per gram body weight/day 
starting from P15 for 10 days, having their gross motoric functions monitored on a daily 
basis. A survival analysis was conducted counting the appearance of tumor-related 
symptoms with subsequent sacrifice as statistical endpoints (Figure 9A). Under this ex-
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Figure 8. Lithium chloride (LiCl) reduces medulloblastoma cell viability in vitro. Colorimetric MTT 
assays after 24h in vitro treatment with 10 mM LiCl decreased cell viability of granule neuron precursor 
cells and medulloblastoma tumor cells from Math1-cre::SmoM2
Fl/+ 
and Ptch1
+/-
  mice, when compared to 
HEK293T, UW473 and GL261 control cells (Pöschl et al. 2014). p<0.01, one sample t-test. Bars show 
mean with SEM. ns not significant. Two asterisks p<0.01.  
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perimental setup, the LiCl group failed to show a statistically relevant survival benefit 
when compared to the Nacl-treated control group (p=0.2734). RT-PCR studies on me-
dulloblastoma samples from both LiCl and NaCl-treated Math1-cre::SmoM2Fl/+ mice 
(NaCl: n=3; LiCl: n=3) suggested the inability of LiCl to enhance, under our treatment 
protocol, the relative expression of Axin2, c-Myc, Dkk1 and Tcf7l2 (also known as TCF-
4), which are well-known Wnt/ β-Catenin target genes (He et al. 1998, Yan et al. 2001, 
Niida et al. 2004, Brown et al. 2012) (Figure 9B). Thus, under the examined conditions, 
LiCl was not able to induce Wnt target genes expression in vivo, explaining the lacking 
effect on overall survival of treated Math1-cre::SmoM2Fl/+ mice. In vitro experiments 
showed that Wnt agonists can represent a promising treatment option for Shh-
dependent medulloblastoma. However, the right substance, dose and application meth-
od for in vivo treatment still has to be defined.  
 
 
 
 
 
 
3.2 The role of activated Shh and Wnt/ β-Catenin signaling in embryonal tumors 
with multilayered rosettes (ETMR) 
 
3.2.1 Activation of Shh and Wnt/ β-Catenin in hGFAP-positive neural forebrain 
precursor cells induces embryonal forebrain tumors in mice 
 
Recent studies show, based on global gene expression analysis, an upregulation of  
Figure 9. In vivo lithium chloride (LiCl) treatment leads to no Wnt activation or survival benefit in 
Math1-cre::SmoM2
Fl/+
 medulloblastoma mice. (A) Kaplan-Meyer curves comparing Math1-
cre::SmoM2
Fl/+
 mice survival after LiCl or NaCl treatment showed no significant survival benefit of the LiCl-
treated mice. (p=0.2734, Log-rank Mantel-Cox test. Censored mice: NaCl n=5, LiCl n=6.). (B) Math1-
cre::SmoM2
Fl/+
 tumor mice were treated daily with 50 mg LiCl (n=15) or NaCl (n=10) per gram body weight 
starting from P15 for 10 days. RT PCR studies showed no up-regulation of Wnt-associated target genes in 
tumor tissue after LiCl (n=3) or NaCl (n=3) treatment. Target genes were normalized to β2-Microglobulin 
(β2M) mRNA. Bars show mean with SEM. 
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Sonic hedgehog (Shh) and Wnt/ β-Catenin targets in a particular subgroup of primitive 
neuroectodermal tumors (PNET) of the central nervous system (Picard et al. 2012), 
which can be identified with the recently coined term of “Embryonal tumor with multi-
layered rosettes” (ETMR) (Paulus et al. 2010, Wesseling 2014). With the purpose of in-
vestigating the possible effects of Shh and Wnt/ β-Catenin signaling in ETMR tumor-
igenesis and in order to establish a mouse model for ETMRs, hGFAP-
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+  mice were generated (see breeding scheme Figure 5). 
These transgenic mice are characterized by a constitutional and simultaneous Shh and 
Wnt/ β-Catenin activation under the control of the hGFAP promotor (Zhuo et al. 2001). In 
order to characterize the brain morphology of these mice, sagittal histological sections at 
P0 were carried out. While the control Ctnnb1(ex3)Fl/+SmoM2Fl/ +  mice showed normal 
development of fore- and hindbrain structures (Fig 10A) with proliferating cells in the 
ventricular zone (Figure 10E), hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ brains revealed the 
formation of extensive forebrain tumors involving both cerebral hemispheres (Figure 
10D), which displayed high mitotic activity, as indicated by ki67 staining (Figure 10H). 
The formation of tumors was unique in the condition with both pathways being simulta-
neously active, since (1) hGFAP-cre::Ctnnb1(ex3)Fl/+ mice, a conditional mouse model 
featuring constitutional Wnt/ β-Catenin activation through β-Catenin mutation (Figure 
10B), showed a disruption of the overall brain morphology as already published (Pöschl 
et al. 2013) and (2) hGFAP-cre::SmoM2Fl/+ mice (Figure 10C) displayed a hyperprolifer-
ative, thickened ventricular zone, that was not seen at later stages (Figure 10 inlay, 
P18), but no forebrain tumor formation (hGFAP-cre::Ctnnb1(ex3)Fl/+ and hGFAP-
cre::SmoM2Fl/+ samples were provided by Dr. Julia Neumann). hGFAP-cre::SmoM2Fl/+ 
mice revealed, as expected, medulloblastoma formation in the cerebellum (Grammel et 
al. 2012). Therefore, it can be concluded that constitutional activation of both Wnt/ β-
Catenin and Shh in hGFAP-positive cells appears to be required and sufficient to induce 
forebrain tumors in hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice. In contrast, the single 
activation of either Shh or Wnt/ β-Catenin is not sufficient to generate the same pheno-
type, as observed in hGFAP-cre::SmoM2Fl/+ or hGFAP-cre::Ctnnb1(ex3)Fl/+ mice. At 
higher magnification, hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ forebrain tumors were char-
acterized by diffuse, densely packed tumor cells with round or polygonal nuclei (Figure 
10I). Similarly to human ETMR samples (Korshunov et al. 2010), histological slides from 
hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice showed areas resembling multi-layered ro-
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settes, consisting of a tumor cell halo surrounding a cell-free, acidophilic zone (Figure 
10J,I arrows).  
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3.2.2 Activation of Shh and Wnt/ β-Catenin in hGFAP-positive neural forebrain 
precursor cells leads to increased proliferation in vitro 
 
Having discovered that constitutional and simultaneous Shh and Wnt/ β-Catenin activa-
Figure 10. Activation of both Shh and Wnt/ β-Catenin in hGFAP-positive neural forebrain precur-
sor cells induces embryonal forebrain tumors in mice. (D) hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 
mice at P0 showed extensive forebrain tumors involving both cerebral hemispheres. (A-C) 
Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+ 
control mice showed, as expected, no brain abnormalities. hGFAP-
cre::Ctnnb1(ex3)
Fl/+
 mice featured a disruption of the forebrain and cerebellum morphology, as previously 
described in Pöschl et al. 2013. hGFAP-cre::SmoM2
Fl/+
 mice presented medulloblastoma formation 
(Grammel et al. 2012) in the cerebellum and no disruption of the overall forebrain architecture. Neverthe-
less, hGFAP-cre::SmoM2
Fl/+
 mice revealed a hyperproliferative, thickened ventricular zone in the fore-
brain, which was no longer detectable at P18 (C, inlay) and lead to no tumor formation (hGFAP-
cre::Ctnnb1(ex3)
Fl/+
, hGFAP-cre::SmoM2
Fl/+
  and hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 samples were 
provided by Julia Neumann). (E-H) Ki67 stainings indicated the presence of diffuse, highly proliferative 
cells within hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+ 
forebrain tumors when compared to control genotypes. 
(J-I) hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 forebrain tumors appeared to resemble some histological fea-
tures of human ETMRs, such as the formation of multilayered rosettes (arrows). H&E Hematoxylin and 
eosin stain. (A,D) sagittal sections. Scale bar in D is 1 mm for A,B,C,D. Scale bar in H is 50 µm for 
E,F,G,H. Scale bar in J is 50 µm. Scale bar in I is 50 µm. 
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tion is able to induce tumor formation in the forebrain of hGFAP-
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice, in vitro experiments were carried out, aiming at a 
morphological and molecular characterization of the induced tumor cells. Neural fore-
brain precursor cells were isolated from the ventricular zone of hGFAP-
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice at P0 and put into primary cell culture for 4 days (see 
methods section). The cultured cells appeared to form cell clusters or spheres (Figure 
11A), whose diameter and density were significantly higher than in the wild type condi-
tion (p=0.0007, p<0.0001 respectively) (Figure 11B and C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hGFAP-cre::Ctnnb1(ex3)Fl/+ spheres were not increased in comparison to control 
spheres, whereas hGFAP-cre::SmoM2Fl/+ spheres revealed an increased diameter 
(p=0.0005) and density (p<0.0001). These results were consistent with the previously 
described detection of a hyperproliferative ventricular zone in hGFAP-cre::SmoM2Fl/+ 
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Figure 11. Activation of both Shh and Wnt/ β-Catenin in hGFAP-positive neural forebrain precursor 
cells from hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+ 
mice leads to increased proliferation in vitro. (A) 
Neural forebrain precursor cells from the ventricular zone of hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 mice 
were isolated at P0 and placed into primary culture for 4 days, leading to the formation of densely packed 
cell spheres. Neural forebrain precursor cells from wild type, hGFAP-cre::Ctnnb1(ex3)
Fl/+ 
and hGFAP-
cre::SmoM2
Fl/+
 mice were cultured following the same protocol (see methods section). (B,C) hGFAP-
cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 spheres showed an increased diameter and density when compared to wild 
type cells (p=0.0007 and p=<0,0001 respectively, unpaired t-test). Similar findings were observed for 
GFAP-cre::SmoM2
Fl/+ 
spheres (diameter p= 0.0005; density p= <0.0001, unpaired t-test). This was con-
sistent with the hyperproliferative ventricular zone detected in hGFAP-cre::SmoM2
Fl/+
 forebrains at P0
 
(see 
Figure 10). Bars show mean with SEM. ns not significant. GB hGFAP-cre::Ctnnb1(ex3)
Fl/+
. GS GFAP-
cre::SmoM2
Fl/+
. GBS  hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
, WT Wild-type. Three asterisks p<0.001. 
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forebrains at P0. Hence, the hGFAP-positive neural forebrain precursor cell population 
originating from hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice presents an increased pro-
liferation rate when compared to control genotypes. 
3.2.3 Interplay of Shh and Wnt/ β-Catenin signaling pathways in murine embry-
onal forebrain tumors in vitro and in vivo 
 
In order to characterize Shh and Wnt/ β-Catenin signaling  in the above mentioned 
spheres, RT-PCR studies were conducted to determine the mRNA expression patterns 
of Patched-1 (Ptch1), a well-known Shh target gene, and  Axin2, a well-known Wnt/ β-
Catenin target gene (Yan et al. 2001, Robbins et al. 2012) (Figure 12). 
 
 
 
 
 
 
As expected, the relative expression of Axin2 and Ptch1 was enhanced in hGFAP-
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ forebrain tumor samples as well as in cultured neural 
forebrain precursor spheres (Figure 12A,B), therefore validating our in vivo and in vitro 
models. hGFAP-cre::SmoM2Fl/+ mice showed an increased relative expression of Ptch1 
alone. Similarly, hGFAP-cre::Ctnnb1(ex3)Fl/+ mice presented sole Wnt/ β-Catenin activa-
tion, which was indicated by Axin2 overexpression. The relative mRNA expression of 
C 
Figure 12. Synergistic effects of Shh and Wnt/ β-Catenin in murine embryonal forebrain tumors in 
vivo and in vitro. (A,B)  Real time PCR studies on hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 mRNA from 
both forebrain tumor tissue and neural forebrain precursor spheres demonstrated a relative overexpres-
sion of  Axin2 and Patched-1 (Ptch1); respectively, two well-known Wnt/ β-Catenin and Shh target genes. 
The relative expression of both Axin2 and Ptch1 in hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 tissue and cell 
spheres appeared to be more elevated than in the hGFAP-cre::Ctnnb1(ex3)
Fl/+ 
or GFAP-cre::SmoM2
Fl/+ 
conditions, thus suggesting a possible synergistic effect of Shh and Wnt/ β-Catenin signalling in hGFAP-
positive cells of the forebrain, perhaps in terms of a reciprocal pathway activation. Target genes were 
normalized to β2-Microglobulin (β2M) mRNA. GB hGFAP-cre::Ctnnb1(ex3)
Fl/+
. GS hGFAP-cre::SmoM2
Fl/+
. 
GBS hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
. Bars show mean with SEM.  
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both Ptch1 and Axin2 in hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice showed the tenden-
cy to be more elevated when compared to the hGFAP-cre::SmoM2Fl/+ or hGFAP-
cre::Ctnnb1(ex3)Fl/+ genotypes, respectively. Hence, the simultaneous activation of Shh 
and Wnt/ β-Catenin in the forebrain of hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice might 
cause a mutual and synergistic effect of these signalling pathways on each other. In or-
der to verify, whether the mRNA upregulation of Shh and Wnt/ β-Catenin target genes in 
our mouse model might be confirmed on a post-translational level, a western blot analy-
sis was carried out. Relative protein levels of Axin2 and Gli2, a Shh target gene (Robbins 
et al. 2012) were quantified by normalization to Beta tubulin expression (Figure 13 A,B). 
The relative protein expression of both Axin2 and Gli2 in forebrain tumor samples from 
hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice was significantly elevated when compared to 
hGFAP-cre control mice (p=0.0007 and p=0.0333, respectively).  
 
 
 
 
 
 
3.3 Propagation of Shh and Wnt/ β-Catenin - dependent embryonal forebrain 
tumors  
 
hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice succumbed at P0 due to extensive tumoral 
masses of the cerebral hemispheres, thus making this first EMTR mouse model unsuita-
ble for investigations at later time points. With the objective of creating a viable mouse 
model for ETMRs and examining the tumor-propagating potential of hGFAP-
Figure 13. hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 mice show posttranslational overexpression of 
Shh and Wnt/ β-Catenin targets. The up-regulation of both Shh and Wnt/ β-Catenin signalling pathways 
in forebrain tumor samples from hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 mice  was confirmed through 
western blot analysis, which showed an increase in relative protein expression of Gli2 (p=0.0333) and 
Axin2 (p=0.0007) when compared to hGFAP-cre control tissue. Target proteins were normalized to Beta 
Tubulin protein expression. GB hGFAP-cre::Ctnnb1(ex3)
Fl/+
. GS hGFAP-cre::SmoM2
Fl/+
. GBS hGFAP-
cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
. Bars show mean with SEM. Three asterisks p<0.001. One asterisk p<0.05. 
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cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ tumor cells, neural forebrain precursors were first  isolat-
ed, put into primary culture and then transplanted into immunodeficient NMRI-Nu/Nu 
(n=8) mice (Figure 14). Hematoxylin and eosin staining revealed tumor formation in the 
host (Figure 14A, arrows), thus demonstrating the ability of hGFAP-
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ forebrain neural precursor cells to propagate after al-
lotransplantation.  Allotransplanted tumors showed the histology of densely packed, blue 
and round cells resembling their primary counterparts and displayed high mitotic activity 
(Figure 14B). Allotransplanted mice (n=8) showed a median survival of 83 days (Figure 
14C). Hence, hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ tumor cells can be propagated in 
host mice, showing that allotransplanted hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ tumor 
cells can represent  a valuable mouse model for ETMRs. This mouse model can be 
used to further study the biology of ETMRs and perform treatment studies. 
 
 
 
 
 
4. Discussion 
 
Previous studies showed that Wnt/ β-Catenin activation is able to inhibit the Shh-driven 
proliferation of cerebellar granule neuron precursor cells (CGNPs) (Lorenz et al. 2011) 
as well as tumor growth in Shh-dependent medulloblastoma (Pöschl et al. 2014). With 
the intent of investigating, whether the newly discovered inhibitory effect of Wnt  over 
Shh might represent a novel approach in the therapy of Shh-associated medulloblasto-
Figure 14. Forebrain tumors of hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+ 
 mice are able to propagate af-
ter allotransplantation into immunodeficient (NMRI Nu/Nu) mice. (A,B) Immunodeficient NMRI Nu/Nu 
(n=8) mice underwent stereotactical injection of cultured hGFAP-cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
 neural 
forebrain precursor cells. H.E. and ki67 stainings revealed the formation of secondary tumors, showing 
densely packed and highly proliferative tumor cells. (B, arrow) The affinity with primary hGFAP-
cre::Ctnnb1(ex3)
Fl/+
SmoM2
Fl/+
  forebrain tumors was suggested by the histological evidence of rosettes 
within the transplanted tumors. (C) Allotransplanted mice (n=8) showed a reduced median survival of 83 
days (censored mice n=3). H&E Hematoxylin and eosin stain. (A) Horizontal section. 
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ma, in vitro and in vivo experiments on medulloblastoma cells and Math1-cre::SmoM2Fl/+ 
mice were conducted using Lithium, a well-known Wnt activator (Stambolic et al. 1996, 
Lancaster et al. 2011). Results showed that Lithium is able to reduce cell viability of 
CGNPs and medulloblastoma tumor cells from Math1-cre::SmoM2Fl/+ and  Ptch1+/-  mice 
in vitro (Figure 8) (Pöschl et al. 2014). On the other hand, the in vivo treatment of 
Math1-cre::SmoM2Fl/+ mice with Lithium under the mentioned experimental setting did 
not lead to the expected survival benefit. Nevertheless, the relative mRNA expression of 
Wnt pathway targets genes in medulloblastoma samples from Math1-cre::SmoM2Fl/+ 
mice was not elevated after Lithium treatment (Figure 9), thus suggesting that the miss-
ing effect on survival might be due to lacking Wnt/ β-Catenin activation. Therefore, con-
sidering the encouraging in vitro results, it is possible to propose the hypothesis that Wnt 
activators may represent a valuable therapeutic option for Shh-associated medulloblas-
toma. Further investigations adopting different dosages of Lithium and other Wnt-
activating substances appear therefore to be required. Another type of embryonal tumor 
of the CNS, the Embryonal tumor with multi-layered rosettes (ETMR), has been recently 
defined as CNS-PNET subset (Korshunov et al. 2012, Wesseling 2014). Amplification of 
the chromosome 19q13.41 miRNA polycistron (C19mC) and/or increased LIN28 expres-
sion have been suggested as possible molecular markers for this type of tumor 
(Korshunov et al. 2014) and are gaining clinical relevance. Furthermore, array-based 
data from CNS-PNETs revealed a possible overexpression of both Wnt and Shh target 
genes in a particular subgroup of tumors, which can be identified with the ETMR subset 
(Picard et al. 2012). With the purpose of examining, whether simultaneous Wnt and Shh 
activation might induce tumorigenesis in the forebrain, hGFAP-
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ were generated, a conditional mouse model presenting 
synchronistic Wnt and Shh upregulation in the hGFAP-positive cell population. hGFAP 
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice developed highly proliferative, extensive forebrain 
tumors with histological resemblance to human ETMRs (Figure 10). RT-PCR and west-
ern blot studies confirmed a specular upregulation of the Wnt and the Shh pathway in 
both tissue samples and cultured forebrain precursor cells from hGFAP-
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice, therefore validating our in vivo and in vitro setting 
(Figure 12-13). In conclusion, this work was able to establish a mouse model for 
ETMRs. Furthermore, a viable allotransplantation-based mouse model as well as a cell 
culture method for ETMR tumor cells have been developed, which might be used for 
future research. With regard to ETMR pathogenesis, this work was able to show that 
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constitutional Wnt and Shh activation in the forebrain might lead to ETMR formation in 
vivo as well as increased proliferation of neural forebrain precursor cells in vitro. It is 
therefore legitimate to postulate that Shh and Wnt upregulation might represent a key 
step in the process of ETMR tumorigenesis. In particular, a possible causal relationship 
between Shh/ Wnt upregulation and other molecular features of ETMRs, such LIN28 
overexpression or C19mC amplification, should be a matter of further investigation. Fur-
thermore, the newly established mouse model might be helpful in defining the exact cel-
lular origin of EMTRs, which still remains unclear. As far as the interplay between Wnt 
and Shh is concerned, the results of this work suggest that the interaction between sim-
ultaneously activated Wnt and Shh in the CNS might be defined in a spatially-related 
manner. In fact, simultaneous Wnt and Shh activation appears to unfold diverging effects 
when comparing forebrain and cerebellum. While Wnt exerts an inhibitory effect over 
Shh-dependent medulloblastoma in the cerebellum (Lorenz et al. 2011, Pöschl et al. 
2014), synchronistic Wnt and Shh activation in the forebrain might be able to induce 
ETMR formation (Figure 10-12). Moreover, the expression patterns of Wnt and Shh tar-
get genes in hGFAP-cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice may have revealed a reciprocal, 
activating interaction between the Wnt and Shh pathway taking place in the forebrain 
(Figure 12). The molecular mechanisms involved in the interplay between Wnt/ β-
Catenin and Shh remain widely unknown, although Gli3-R, the repressive form of the 
Shh-associated transcription factor Gli3, has been suggested to be play an important 
role in the modulation of the Wnt/ Shh interplay (Alvarez-Medina et al. 2008). Deeper 
understanding of the molecular underpinnings characterizing the interaction between 
these two pathways might shed light onto possible new targets of therapy for embryonal 
brain tumors, whereas a diverging approach appears to be necessary when considering 
Shh-dependent medulloblastoma or ETMRs. Indeed, Wnt/ β-Catenin activating sub-
stances, such as Lithium (Lancaster et al. 2011), might represent a valuable therapeutic 
approach for Shh-associated medulloblastoma. ETMR therapy, on contrary, might be 
focused on molecules curbing the overexpression of both the Wnt and Shh pathway, 
such as Vismodegib or PKF115-584 (Lepourcelet et al. 2004, Sekulic et al. 2012). 
5. Summary 
 
This work investigates the expression and interaction of Shh or Wnt/ β-Catenin in murine 
Shh-dependent medulloblastoma and ETMRs. The first part of the results focuses on 
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Shh-dependent medulloblastoma. Previous studies were able to show that Wnt/ β-
Catenin activation might be able to inhibit Shh-associated medulloblastoma growth 
through downregulation of the Shh pathway. Considering a possible therapeutic ap-
proach, in vitro and in vivo treatments with lithium chloride, a well-known Wnt/ β-Catenin 
agonist, were carried out. Whereas lithium chloride treatment in vitro resulted in a de-
crease of granule neuron precursor and tumor cell viability, in vivo treatment of Math1-
cre::SmoM2Fl/+ mice did not show an increased expression of Wnt signalling target 
genes or a survival benefit under the applied dosage and treatment period. The second 
part of the results deals with the establishment and characterisation of a mouse model 
for ETMRs, for which an upregulation of both Wnt/ β-Catenin and Sonic-hedgehog has 
been recently postulated. In order to achieve a synchronistic activation of these path-
ways in forebrain precursor cells, hGFAPcre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice were gen-
erated. These mice developed highly proliferative embryonal forebrain tumors, which 
histologically resembled human ETMRs. RT-PCR and Western blot studies were con-
ducted on both tissue samples and cultured cells from the hGFAP-
cre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ forebrain tumors, demonstrating an overexpression of 
both Sonic-hedgehog and Wnt/βCatenin associated targets. Finally, forebrain tumors 
from hGFAPcre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ mice could be propagated into Nu/Nu mice. 
Overall, the results of this work show that the interplay of the Sonic hedgehog and Wnt/ 
β-Catenin signalling pathway are highly cell- and context specific. The tumor antagonis-
tic effect of Wnt/ β-Catenin signalling on Shh-dependent medulloblastoma growth impli-
cates that Wnt/ β-Catenin agonists could represent a new treatment strategy for these 
tumors. In forebrain precursor cells, the co-activation of both the Sonic hedgehog and 
Wnt/ β-Catenin signalling pathway appears to be necessary to induce embryonal tumors, 
which can be identified as ETMRs. Hence, a detailed understanding of the molecular 
interplay of these pathways will be needed to further improve targeted therapy. In this 
context, Wnt or Shh antagonists might be potential candidate drugs for the specific 
treatment of ETMRs.  
6. Zusammenfassung 
 
Diese wissenschaftliche Arbeit untersucht die Expression und Interaktion von Sonic 
hedgehog (Shh) und Wnt/ β-Catenin in Shh-assoziiertem Medulloblastom und ETMRs 
durch den Einsatz von Mausmodellen. Der erste Teil der Ergebnisse ist auf das Shh-
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induzierte Medulloblastom fokussiert. Vorherige Studien konnten zeigen, dass die Akti-
vierung von Wnt/ β-Catenin in der Lage ist, das Tumorwachstum von Shh-assoziierten 
Medulloblastomen durch Shh-Inhibition zu drosseln. Lithium, ein bekannter Wnt Aktiva-
tor, wurde in Hinsicht auf einen möglichen therapeutischen Einsatz für eine Reihe von in 
vivo- und in vitro  Experimenten verwendet. Während Lithium die in vitro Proliferation 
von zerebellären Körnervorläuferzellen und Tumorzellen reduzieren konnte, ergab die in 
vivo Behandlung von Math1-cre::SmoM2Fl/+  Mäusen keine Überexpression der Wnt-
Zielgene sowie keinen Überlebensvorteil unter der applizierten Dosis und dem ange-
wandten Zeitraum. Der zweite Teil der Ergebnisse beschäftigt sich mit der Etablierung 
und Charakterisierung von einem Mausmodell für ETMRs, für die eine Überexpression 
von Wnt und Shh neulich nahegelegt wurde. hGFAPcre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ Mäu-
se wurden mit dem Ziel einer synchronistischen Aktivierung dieser Signalwege in Vor-
derhinrvorläuferzellen generiert. Diese Mäuse zeigten massive, hoch proliferative Tumo-
re des Vorderhirns, die in ihrer Histologie den humanen ETMRs ähnelten. RT PCR und 
Western blot Analysen demonstrierten eine Überexpression von Shh- und Wnt-
assoziierten Zielgenen sowohl im Tumorgewebe als auch in kultivierten Tumorzellen von 
hGFAPcre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ Mäusen. Zudem zeigten die Vorderhirntumore von 
hGFAPcre::Ctnnb1(ex3)Fl/+SmoM2Fl/+ Mäusen die Fähigkeit, in Nu/Nu zu propagieren. 
Zusammenfassend weisen die Ergebnisse dieser Arbeit darauf hin, dass die Interaktion 
zwischen den Shh und Wnt Signalwegen stark zell- und kontextspezifisch ist. Der inhibi-
torische Effekt von Wnt/ β-Catenin auf das Shh-abhängige Medulloblastom könnte die 
Grundlage eines neuen therapeutischen Ansatzes für Medulloblastome sein, bei dem 
Wnt-aktivierende Substanzen möglicherweise zum Einsatz kommen könnten. Die 
gleichzeitige Aktivierung von Shh und Wnt scheint zudem nötig zu sein, um Vorderhirn-
tumore zu induzieren, die als ETMRs identifiziert werden können. Dementsprechend 
wird ein detaillierter Aufschluss der molekularen Interaktion zwischen Shh und Wnt  in 
der Zukunft notwendig sein, um zielgerichtete Therapien entwickeln zu können. Wnt- 
und Shh-inhibierende Substanzen könnten in diesem Kontext potentielle, spezifische 
Medikamente für die Therapie von ETMRs darstellen. 
 
"
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